NDAINTRAMUSCULARFOR SUSPENSION, EXTENDED RELEASE
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
TRIPTODUR KIT (triptorelin) by R-Pharm US is 12. Approved for prostate cancer, central precocious puberty, endometriosis. First approved in 2017.
Drug data last refreshed 20h ago
Mechanism of Action
12.1 Mechanism of Action Triptorelin is a GnRH agonist. 12.2 Pharmacodynamics Following the first administration, there is a transient surge in circulating levels of LH, FSH, testosterone, and estradiol [see ] . After chronic and continuous administration, by 4 weeks after initiation of therapy, a…
Worked on TRIPTODUR KIT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.